Amgen Inc

1 products tracked · names used in filings: Amgen Inc

Upcoming milestones

No upcoming milestones listed.

Recent milestones

Thu 22 Oct 2026🇺🇸 FDA approval

FDA approves biosimilar Pavblu (aflibercept-ayyh)

Amgen Inc; BLA761298; Biosimilar; injectable · source

Thu 18 Dec 2025🇺🇸 PDUFA datecompany-announced

Amgen Inc: PDUFA target action date

Amgen Inc (AMGN); "standard of care in subjects with relapsed ES-SCLC after platinum-based first-line chemotherapy was accepted with a PDUFA date of December 18, 2025."; filed 2025-11-04 · source

Sun 14 Dec 2025🇺🇸 PDUFA datecompany-announced

Amgen Inc: PDUFA target action date

Amgen Inc (AMGN); "Food and Drug Administration (FDA) review of the MINT Phase 3 data in patients with generalized myasthenia gravis is ongoing, with a PDUFA date of December 14, 2025."; filed 2025-11-04 · source

Products

	Product	Status	Approved
🇺🇸	Pavblu aflibercept-ayyh	Approved	2026-10-22

Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.